Rasio utang marang kapitalisasi buku: Immunocore Holdings plc (IMCR)

Immunocore Holdings plc (IMCR) revenues are based on the commercialization of the innovative KIMMTRAK treatment for uveal melanoma, with production carried out at certified facilities operating at maximum capacity. This price chart serves as an indicator of the asset's value, which stands at 1.08. Business development relies on partnerships with global pharma leaders to co-create new methods of immune activation in oncology.

Immunocore Holdings plc (IMCR) optimizes capital expenditures by outsourcing clinical trials and manufacturing, which minimizes the need for costly assets. The total liabilities-to-equity ratio measures financial stability and leverage, where low values confirm safety from default but signal conservative investing, as clearly reflected by the total debt-to-equity coverage ratio.